Understanding FLT3 in AML: What It Means and How It’s Treated image

Understanding FLT3 in AML: What It Means and How It’s Treated

May 15, 2025
03:00PM - 04:00PM EDT
Online Event
Overview

Join us for a special session focused on FLT3 mutations in Acute Myeloid Leukemia (AML), one of the most common genetic changes found in AML patients. Dr. Nicholas Short from MD Anderson Cancer Center will explain what FLT3 mutations are, how they affect treatment decisions, and what targeted therapies are available today. Whether you’re newly diagnosed or navigating ongoing treatment, this session will help you understand the role FLT3 plays in your AML journey and what questions to ask your doctor.

Agenda
3:00 PM
Introduction
Marilú Nájera Flores

Marilu introduces the agenda for the event and featured speaker Dr. Nicholas Short

3:05 PM
Presentation
Nicholas Short, MD

 

Dr. Short talks about FLT3 mutations in AML

3:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators
Healthtree contact Marilú Nájera Flores

Marilú Nájera Flores

Marilu Najera is an International Medical Graduate and an Event Operations Manager at the HealthTree Foundation. Her journey through several patient-centered roles has deepened her passion for advocacy, education, and connection. Now, as part of the education team, she is leading efforts to grow HealthTree’s newest community: ALL (acute lymphoblastic leukemia). She organizes patient-friendly webinars with expert speakers and works to ensure that patients and families feel informed, empowered, and supported. Marilu brings empathy, joy, and warmth to every project. Outside of work, she loves to travel, connect with others, and spend time with her loved ones—especially her nephews (being an aunt is her absolute favorite role in life!).
Healthtree contact Nicholas Short, MD

Nicholas Short, MD

Dr. Nicholas Short is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. He specializes in adult acute leukemias, with a focus on targeted therapies and measurable residual disease (MRD). Dr. Short leads numerous phase I and II clinical trials exploring new treatment options for AML and ALL. He has authored over 200 peer-reviewed publications and has presented his research at major conferences like ASH and ASCO. His work has earned him prestigious honors, including the ASCO Young Investigator Award and the ASH Junior Faculty Scholar Award.